Loading…
B.02 Recessive mutations in ATP8A2 cause severe hypotonia, cognitive impairment, hyperkinetic movement disorders and progressive optic atrophy
Background: ATP8A2 mutations have only recently been associated with human disease. We present the clinical features from the largest cohort of patients with this disorder reported to date. Methods: An observational study of 9 unreported and 2 previously reported patients with biallelic ATP8A2 mutat...
Saved in:
Published in: | Canadian journal of neurological sciences 2018-06, Vol.45 (s2), p.S12-S12 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c1810-17208acff086640d8bef8c48ef504271df81e24f69230a12fc85758a666abe643 |
---|---|
cites | |
container_end_page | S12 |
container_issue | s2 |
container_start_page | S12 |
container_title | Canadian journal of neurological sciences |
container_volume | 45 |
creator | McMillan, HJ Telegrafi, A Singleton, A Cho, M Lelli, D Lynn, FC Griffin, J Asamoah, A Rinne, T Erasmus, CE Koolen, DA Haaxma, CA Keren, B Doummar, D Mignot, C Thompson, I Velsher, L Dehghani, M Vahidi Mehrjardi, M Maroofian, R Tchan, M Simons, C Christodoulou, J Martín-Hernández, E Guillen Sacoto, MJ Henderson, LB McLaughlin, H Molday, LL Molday, RS Yoon, G |
description | Background: ATP8A2 mutations have only recently been associated with human disease. We present the clinical features from the largest cohort of patients with this disorder reported to date. Methods: An observational study of 9 unreported and 2 previously reported patients with biallelic ATP8A2 mutations was carried out at multiple centres. Results: The mean age of the cohort was 9.4 years old (range: 2.5-28 yrs). All patients demonstrated developmental delay, severe hypotonia and movement disorders: chorea/choreoathetosis (100%), dystonia (27%) or facial dyskinesia (18%). Hypotonia was apparent at birth (70%) or before 6 months old (100%). Optic atrophy was observed in 75% of patients who had a funduscopic examination. MRI of the brain was normal for most patients with a small proportion showing mild cortical atrophy (30%), delayed myelination (20%) and/or hypoplastic optic nerves (20%). Epilepsy was seen in two older patients. Conclusions: ATP8A2 gene mutations have emerged as a cause of a novel phenotype characterized by developmental delay, severe hypotonia and hyperkinetic movement disorders. Optic atrophy is common and may only become apparent in the first few years of life, necessitating repeat ophthalmologic evaluation. Early recognition of the cardinal features of this condition will facilitate diagnosis of this disorder. |
doi_str_mv | 10.1017/cjn.2018.90 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2799851354</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_cjn_2018_90</cupid><sourcerecordid>2799851354</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1810-17208acff086640d8bef8c48ef504271df81e24f69230a12fc85758a666abe643</originalsourceid><addsrcrecordid>eNptkE1LAzEQhoMoWD9O_oGAR906STfZ7LEWv6CgiJ6XNDupqW6yJruF_gl_s11a8OJpYHjmfYeHkAsGYwasuDErP-bA1LiEAzLiIIoMmBCHZAQTVmRMFuyYnKS0AuBSyHxEfm7HwOkrGkzJrZE2fac7F3yiztPp24uacmp0n5AmXGNE-rFpQxe809fUhKV33XDlmla72KDvrgcA46fz2DlDm7DGYU1rl0KsMSaqfU3bGJZx3xjaAdRdDO3H5owcWf2V8Hw_T8n7_d3b7DGbPz88zabzzDDFIGMFB6WNtaCkzKFWC7TK5AqtgJwXrLaKIc-tLPkENOPWKFEIpaWUeoEyn5ySy13u9pPvHlNXrUIf_bay4kVZKsEmYqCudpSJIaWItmqja3TcVAyqQXi1FV4NwqsStnS2p3WziK5e4l_of_wvYtyESw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2799851354</pqid></control><display><type>article</type><title>B.02 Recessive mutations in ATP8A2 cause severe hypotonia, cognitive impairment, hyperkinetic movement disorders and progressive optic atrophy</title><source>Cambridge Journals Online</source><creator>McMillan, HJ ; Telegrafi, A ; Singleton, A ; Cho, M ; Lelli, D ; Lynn, FC ; Griffin, J ; Asamoah, A ; Rinne, T ; Erasmus, CE ; Koolen, DA ; Haaxma, CA ; Keren, B ; Doummar, D ; Mignot, C ; Thompson, I ; Velsher, L ; Dehghani, M ; Vahidi Mehrjardi, M ; Maroofian, R ; Tchan, M ; Simons, C ; Christodoulou, J ; Martín-Hernández, E ; Guillen Sacoto, MJ ; Henderson, LB ; McLaughlin, H ; Molday, LL ; Molday, RS ; Yoon, G</creator><creatorcontrib>McMillan, HJ ; Telegrafi, A ; Singleton, A ; Cho, M ; Lelli, D ; Lynn, FC ; Griffin, J ; Asamoah, A ; Rinne, T ; Erasmus, CE ; Koolen, DA ; Haaxma, CA ; Keren, B ; Doummar, D ; Mignot, C ; Thompson, I ; Velsher, L ; Dehghani, M ; Vahidi Mehrjardi, M ; Maroofian, R ; Tchan, M ; Simons, C ; Christodoulou, J ; Martín-Hernández, E ; Guillen Sacoto, MJ ; Henderson, LB ; McLaughlin, H ; Molday, LL ; Molday, RS ; Yoon, G</creatorcontrib><description>Background: ATP8A2 mutations have only recently been associated with human disease. We present the clinical features from the largest cohort of patients with this disorder reported to date. Methods: An observational study of 9 unreported and 2 previously reported patients with biallelic ATP8A2 mutations was carried out at multiple centres. Results: The mean age of the cohort was 9.4 years old (range: 2.5-28 yrs). All patients demonstrated developmental delay, severe hypotonia and movement disorders: chorea/choreoathetosis (100%), dystonia (27%) or facial dyskinesia (18%). Hypotonia was apparent at birth (70%) or before 6 months old (100%). Optic atrophy was observed in 75% of patients who had a funduscopic examination. MRI of the brain was normal for most patients with a small proportion showing mild cortical atrophy (30%), delayed myelination (20%) and/or hypoplastic optic nerves (20%). Epilepsy was seen in two older patients. Conclusions: ATP8A2 gene mutations have emerged as a cause of a novel phenotype characterized by developmental delay, severe hypotonia and hyperkinetic movement disorders. Optic atrophy is common and may only become apparent in the first few years of life, necessitating repeat ophthalmologic evaluation. Early recognition of the cardinal features of this condition will facilitate diagnosis of this disorder.</description><identifier>ISSN: 0317-1671</identifier><identifier>EISSN: 2057-0155</identifier><identifier>DOI: 10.1017/cjn.2018.90</identifier><language>eng</language><publisher>New York, USA: Cambridge University Press</publisher><subject>Atrophy ; CSCN / CACN CHAIR’S SELECT ABSTRACTS ; Movement disorders ; Mutation ; PLATFORM PRESENTATIONS</subject><ispartof>Canadian journal of neurological sciences, 2018-06, Vol.45 (s2), p.S12-S12</ispartof><rights>The Canadian Journal of Neurological Sciences Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1810-17208acff086640d8bef8c48ef504271df81e24f69230a12fc85758a666abe643</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S0317167118000902/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,72960</link.rule.ids></links><search><creatorcontrib>McMillan, HJ</creatorcontrib><creatorcontrib>Telegrafi, A</creatorcontrib><creatorcontrib>Singleton, A</creatorcontrib><creatorcontrib>Cho, M</creatorcontrib><creatorcontrib>Lelli, D</creatorcontrib><creatorcontrib>Lynn, FC</creatorcontrib><creatorcontrib>Griffin, J</creatorcontrib><creatorcontrib>Asamoah, A</creatorcontrib><creatorcontrib>Rinne, T</creatorcontrib><creatorcontrib>Erasmus, CE</creatorcontrib><creatorcontrib>Koolen, DA</creatorcontrib><creatorcontrib>Haaxma, CA</creatorcontrib><creatorcontrib>Keren, B</creatorcontrib><creatorcontrib>Doummar, D</creatorcontrib><creatorcontrib>Mignot, C</creatorcontrib><creatorcontrib>Thompson, I</creatorcontrib><creatorcontrib>Velsher, L</creatorcontrib><creatorcontrib>Dehghani, M</creatorcontrib><creatorcontrib>Vahidi Mehrjardi, M</creatorcontrib><creatorcontrib>Maroofian, R</creatorcontrib><creatorcontrib>Tchan, M</creatorcontrib><creatorcontrib>Simons, C</creatorcontrib><creatorcontrib>Christodoulou, J</creatorcontrib><creatorcontrib>Martín-Hernández, E</creatorcontrib><creatorcontrib>Guillen Sacoto, MJ</creatorcontrib><creatorcontrib>Henderson, LB</creatorcontrib><creatorcontrib>McLaughlin, H</creatorcontrib><creatorcontrib>Molday, LL</creatorcontrib><creatorcontrib>Molday, RS</creatorcontrib><creatorcontrib>Yoon, G</creatorcontrib><title>B.02 Recessive mutations in ATP8A2 cause severe hypotonia, cognitive impairment, hyperkinetic movement disorders and progressive optic atrophy</title><title>Canadian journal of neurological sciences</title><addtitle>Can. J. Neurol. Sci</addtitle><description>Background: ATP8A2 mutations have only recently been associated with human disease. We present the clinical features from the largest cohort of patients with this disorder reported to date. Methods: An observational study of 9 unreported and 2 previously reported patients with biallelic ATP8A2 mutations was carried out at multiple centres. Results: The mean age of the cohort was 9.4 years old (range: 2.5-28 yrs). All patients demonstrated developmental delay, severe hypotonia and movement disorders: chorea/choreoathetosis (100%), dystonia (27%) or facial dyskinesia (18%). Hypotonia was apparent at birth (70%) or before 6 months old (100%). Optic atrophy was observed in 75% of patients who had a funduscopic examination. MRI of the brain was normal for most patients with a small proportion showing mild cortical atrophy (30%), delayed myelination (20%) and/or hypoplastic optic nerves (20%). Epilepsy was seen in two older patients. Conclusions: ATP8A2 gene mutations have emerged as a cause of a novel phenotype characterized by developmental delay, severe hypotonia and hyperkinetic movement disorders. Optic atrophy is common and may only become apparent in the first few years of life, necessitating repeat ophthalmologic evaluation. Early recognition of the cardinal features of this condition will facilitate diagnosis of this disorder.</description><subject>Atrophy</subject><subject>CSCN / CACN CHAIR’S SELECT ABSTRACTS</subject><subject>Movement disorders</subject><subject>Mutation</subject><subject>PLATFORM PRESENTATIONS</subject><issn>0317-1671</issn><issn>2057-0155</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNptkE1LAzEQhoMoWD9O_oGAR906STfZ7LEWv6CgiJ6XNDupqW6yJruF_gl_s11a8OJpYHjmfYeHkAsGYwasuDErP-bA1LiEAzLiIIoMmBCHZAQTVmRMFuyYnKS0AuBSyHxEfm7HwOkrGkzJrZE2fac7F3yiztPp24uacmp0n5AmXGNE-rFpQxe809fUhKV33XDlmla72KDvrgcA46fz2DlDm7DGYU1rl0KsMSaqfU3bGJZx3xjaAdRdDO3H5owcWf2V8Hw_T8n7_d3b7DGbPz88zabzzDDFIGMFB6WNtaCkzKFWC7TK5AqtgJwXrLaKIc-tLPkENOPWKFEIpaWUeoEyn5ySy13u9pPvHlNXrUIf_bay4kVZKsEmYqCudpSJIaWItmqja3TcVAyqQXi1FV4NwqsStnS2p3WziK5e4l_of_wvYtyESw</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>McMillan, HJ</creator><creator>Telegrafi, A</creator><creator>Singleton, A</creator><creator>Cho, M</creator><creator>Lelli, D</creator><creator>Lynn, FC</creator><creator>Griffin, J</creator><creator>Asamoah, A</creator><creator>Rinne, T</creator><creator>Erasmus, CE</creator><creator>Koolen, DA</creator><creator>Haaxma, CA</creator><creator>Keren, B</creator><creator>Doummar, D</creator><creator>Mignot, C</creator><creator>Thompson, I</creator><creator>Velsher, L</creator><creator>Dehghani, M</creator><creator>Vahidi Mehrjardi, M</creator><creator>Maroofian, R</creator><creator>Tchan, M</creator><creator>Simons, C</creator><creator>Christodoulou, J</creator><creator>Martín-Hernández, E</creator><creator>Guillen Sacoto, MJ</creator><creator>Henderson, LB</creator><creator>McLaughlin, H</creator><creator>Molday, LL</creator><creator>Molday, RS</creator><creator>Yoon, G</creator><general>Cambridge University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>201806</creationdate><title>B.02 Recessive mutations in ATP8A2 cause severe hypotonia, cognitive impairment, hyperkinetic movement disorders and progressive optic atrophy</title><author>McMillan, HJ ; Telegrafi, A ; Singleton, A ; Cho, M ; Lelli, D ; Lynn, FC ; Griffin, J ; Asamoah, A ; Rinne, T ; Erasmus, CE ; Koolen, DA ; Haaxma, CA ; Keren, B ; Doummar, D ; Mignot, C ; Thompson, I ; Velsher, L ; Dehghani, M ; Vahidi Mehrjardi, M ; Maroofian, R ; Tchan, M ; Simons, C ; Christodoulou, J ; Martín-Hernández, E ; Guillen Sacoto, MJ ; Henderson, LB ; McLaughlin, H ; Molday, LL ; Molday, RS ; Yoon, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1810-17208acff086640d8bef8c48ef504271df81e24f69230a12fc85758a666abe643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Atrophy</topic><topic>CSCN / CACN CHAIR’S SELECT ABSTRACTS</topic><topic>Movement disorders</topic><topic>Mutation</topic><topic>PLATFORM PRESENTATIONS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McMillan, HJ</creatorcontrib><creatorcontrib>Telegrafi, A</creatorcontrib><creatorcontrib>Singleton, A</creatorcontrib><creatorcontrib>Cho, M</creatorcontrib><creatorcontrib>Lelli, D</creatorcontrib><creatorcontrib>Lynn, FC</creatorcontrib><creatorcontrib>Griffin, J</creatorcontrib><creatorcontrib>Asamoah, A</creatorcontrib><creatorcontrib>Rinne, T</creatorcontrib><creatorcontrib>Erasmus, CE</creatorcontrib><creatorcontrib>Koolen, DA</creatorcontrib><creatorcontrib>Haaxma, CA</creatorcontrib><creatorcontrib>Keren, B</creatorcontrib><creatorcontrib>Doummar, D</creatorcontrib><creatorcontrib>Mignot, C</creatorcontrib><creatorcontrib>Thompson, I</creatorcontrib><creatorcontrib>Velsher, L</creatorcontrib><creatorcontrib>Dehghani, M</creatorcontrib><creatorcontrib>Vahidi Mehrjardi, M</creatorcontrib><creatorcontrib>Maroofian, R</creatorcontrib><creatorcontrib>Tchan, M</creatorcontrib><creatorcontrib>Simons, C</creatorcontrib><creatorcontrib>Christodoulou, J</creatorcontrib><creatorcontrib>Martín-Hernández, E</creatorcontrib><creatorcontrib>Guillen Sacoto, MJ</creatorcontrib><creatorcontrib>Henderson, LB</creatorcontrib><creatorcontrib>McLaughlin, H</creatorcontrib><creatorcontrib>Molday, LL</creatorcontrib><creatorcontrib>Molday, RS</creatorcontrib><creatorcontrib>Yoon, G</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Canadian journal of neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McMillan, HJ</au><au>Telegrafi, A</au><au>Singleton, A</au><au>Cho, M</au><au>Lelli, D</au><au>Lynn, FC</au><au>Griffin, J</au><au>Asamoah, A</au><au>Rinne, T</au><au>Erasmus, CE</au><au>Koolen, DA</au><au>Haaxma, CA</au><au>Keren, B</au><au>Doummar, D</au><au>Mignot, C</au><au>Thompson, I</au><au>Velsher, L</au><au>Dehghani, M</au><au>Vahidi Mehrjardi, M</au><au>Maroofian, R</au><au>Tchan, M</au><au>Simons, C</au><au>Christodoulou, J</au><au>Martín-Hernández, E</au><au>Guillen Sacoto, MJ</au><au>Henderson, LB</au><au>McLaughlin, H</au><au>Molday, LL</au><au>Molday, RS</au><au>Yoon, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>B.02 Recessive mutations in ATP8A2 cause severe hypotonia, cognitive impairment, hyperkinetic movement disorders and progressive optic atrophy</atitle><jtitle>Canadian journal of neurological sciences</jtitle><addtitle>Can. J. Neurol. Sci</addtitle><date>2018-06</date><risdate>2018</risdate><volume>45</volume><issue>s2</issue><spage>S12</spage><epage>S12</epage><pages>S12-S12</pages><issn>0317-1671</issn><eissn>2057-0155</eissn><abstract>Background: ATP8A2 mutations have only recently been associated with human disease. We present the clinical features from the largest cohort of patients with this disorder reported to date. Methods: An observational study of 9 unreported and 2 previously reported patients with biallelic ATP8A2 mutations was carried out at multiple centres. Results: The mean age of the cohort was 9.4 years old (range: 2.5-28 yrs). All patients demonstrated developmental delay, severe hypotonia and movement disorders: chorea/choreoathetosis (100%), dystonia (27%) or facial dyskinesia (18%). Hypotonia was apparent at birth (70%) or before 6 months old (100%). Optic atrophy was observed in 75% of patients who had a funduscopic examination. MRI of the brain was normal for most patients with a small proportion showing mild cortical atrophy (30%), delayed myelination (20%) and/or hypoplastic optic nerves (20%). Epilepsy was seen in two older patients. Conclusions: ATP8A2 gene mutations have emerged as a cause of a novel phenotype characterized by developmental delay, severe hypotonia and hyperkinetic movement disorders. Optic atrophy is common and may only become apparent in the first few years of life, necessitating repeat ophthalmologic evaluation. Early recognition of the cardinal features of this condition will facilitate diagnosis of this disorder.</abstract><cop>New York, USA</cop><pub>Cambridge University Press</pub><doi>10.1017/cjn.2018.90</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0317-1671 |
ispartof | Canadian journal of neurological sciences, 2018-06, Vol.45 (s2), p.S12-S12 |
issn | 0317-1671 2057-0155 |
language | eng |
recordid | cdi_proquest_journals_2799851354 |
source | Cambridge Journals Online |
subjects | Atrophy CSCN / CACN CHAIR’S SELECT ABSTRACTS Movement disorders Mutation PLATFORM PRESENTATIONS |
title | B.02 Recessive mutations in ATP8A2 cause severe hypotonia, cognitive impairment, hyperkinetic movement disorders and progressive optic atrophy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A44%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=B.02%20Recessive%20mutations%20in%20ATP8A2%20cause%20severe%20hypotonia,%20cognitive%20impairment,%20hyperkinetic%20movement%20disorders%20and%20progressive%20optic%20atrophy&rft.jtitle=Canadian%20journal%20of%20neurological%20sciences&rft.au=McMillan,%20HJ&rft.date=2018-06&rft.volume=45&rft.issue=s2&rft.spage=S12&rft.epage=S12&rft.pages=S12-S12&rft.issn=0317-1671&rft.eissn=2057-0155&rft_id=info:doi/10.1017/cjn.2018.90&rft_dat=%3Cproquest_cross%3E2799851354%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1810-17208acff086640d8bef8c48ef504271df81e24f69230a12fc85758a666abe643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2799851354&rft_id=info:pmid/&rft_cupid=10_1017_cjn_2018_90&rfr_iscdi=true |